ptis Therapeutics (COEP) - 2025 Q4 - Annual Report

Acquisition and Financial History - Coeptis Therapeutics Holdings, Inc. completed the acquisition of Coeptis Therapeutics, Inc. in an all-stock transaction on October 28, 2022, through a reverse merger[9] - The historical financial statements prior to the acquisition reflect those of Coeptis Sub, with consolidated business information following the merger[9] - The report includes audited consolidated financial statements for the years ended December 31, 2025, and December 31, 2024[10] Financial Performance and Profitability Concerns - The company has a history of losses and expects to incur further losses in the future, raising concerns about achieving or maintaining profitability[18] - There is a history of losses, and the company expects to incur further losses in the future, impacting profitability[18] - There is substantial doubt about the company's ability to continue as a going concern[18] Drug Development and Regulatory Challenges - The drug development and approval process is described as uncertain, time-consuming, and expensive, which may adversely affect the company's business[18] - Regulatory approval processes are costly and lengthy, and the company may not successfully obtain all required approvals[18] - The regulatory approval process is costly and lengthy, and the company may not obtain all required approvals[18] Growth and Operational Risks - The company may face difficulties in managing anticipated growth, which could negatively impact operations[18] - The company may face challenges in successfully implementing its growth strategy in a timely manner[18] Competition and Market Risks - The company acknowledges risks related to competition in the biotechnology and pharmaceutical industries, which could affect revenues and profits[18] - Competition in the biotechnology and pharmaceutical industries may lead to lower revenues or profits due to competing products[18] - Federal laws on drug importation could introduce lower-cost versions of future products, adversely affecting revenues[18] - Healthcare reform measures could negatively impact the company's business[18] Financing and Management - The company emphasizes the importance of obtaining financing to continue operations[18] - The company needs to obtain financing to continue its operations[18] - Retaining the current senior management team and attracting qualified personnel is critical for the company's success[18]